Tratamiento de verrugas múltiples con interferón alfa 2b subcutáneo. estudio prospectivo en 23 pacientes / Treatment of multiple warts with subcutaneous interferon alfa 2b. A prospective study in 23 patients

Las verrugas son lesiones cutáneas y mucosas causadas por el virus papiloma humano. Su presencia puede generar un problema físico, estético, social e impedir al paciente la realización de actividades de la vida cotidiana. En este trabajo realizamos un estudio experimental prospectivo en pacientes con edades comprendidas entre 3 y 75 años, que consultaron al Servicio de Dermatología del Hospital de Clínicas José de San Martín, desde enero de 2014 a julio de 2015, utilizando interferón alfa 2b subcutáneo para el tratamiento de verrugas múltiples refractarias a tratamientos previos. La cantidad de lesiones debía ser mayor a 10 verrugas por paciente y se evaluó la respuesta en total, parcial o nula. Se recolectaron datos de edad, género, topografía y morfología de las lesiones, síntomas asociados, antecedentes previos y efectos adversos. Se realizó un seguimiento clínico, dermatoscópico e iconográfico semanal. Se evaluó un total de 23 pacientes con una edad media de 25,91 años. De éstos, el 56,5% fue mujeres y el 43,5% varones. El 87% presentó verrugas vulgares, 47,8% verrugas peri y subungueales, 17,4% verrugas podales y 39,1% verrugas mixtas. La respuesta terapéutica luego de completado el tratamiento fue total en 56,5%, parcial en 39,1% y nula en 4,3% de los pacientes. Se presentaron efectos adversos en el 13% y, del total de los pacientes, presentaron una óptima respuesta los menores de 15 años de edad (AU)

Cutaneous and mucous warts are caused by the human papilloma virus. Their presence can create a physical and social problem, limiting the patient in performing activities of daily life. In this study we performed a prospective pilot study in patients aged between 3 and 75 years, who consulted the Department of Dermatology at Hospital de Clínicas José de San Martin, from January 2014 to July 2015, using subcutaneous interferon alfa-2b for the treatment of multiple warts refractory to previous treatments. The number of lesions should be increased to 10 warts per patient and we evaluated the response in total, partial or nule. Data on age, gender, topography and morphology of lesions, associated symptoms, prior history and adverse effects were collected. We conducted a weekly clinical, dermoscopic and iconographic up. A total of 23 patients were evaluated with a mean age of 25.91 years. Of these, 56.5% were women and 43.5% men. 87% had common warts, 47.8 peri and subungual warts, 17.4% podal warts and 39.1% mixed warts. The therapeutic response after treatment was total in 56, 5%, partial in 39.1% and nule in 4.3% of patients. Adverse events occurred in 13% and of all patients, those with optimal response were those under 15 years old (AU)

Intralesional immunotherapy with killed Mycobacterium indicus pranii vaccine for the treatment of extensive cutaneous warts.

Background: Multiple cutaneous warts in adults are often symptomatic, cosmetically disabling, and difficult to treat. Killed Mycobacterium indicus pranii (previously known as Mycobacterium w, popularly known as Mw) vaccine has earlier been investigated in genital warts with encouraging results. Objective: To evaluate the efficacy and safety profile of intralesional injected killed Mw vaccine for the treatment of extensive extragenital cutaneous warts. Methods: In this study, a retrospective analysis of medical records was performed in patients with cutaneous warts treated with intralesional Mw vaccine. Only patients with more than 5 extra‑genital warts, involving at least two body sites and which had not shown any signs of spontaneous regression over 6 months were treated with the vaccine. Results: Forty four patients were treated with intralesional Mw vaccine. The mean number of warts was 41.5 ± 25.7 with a disease duration of 3.1 ± 2.5 years. Complete clearance was achieved in 24 (54.5%) patients with a mean of 3.4 ± 1.1 intralesional injections. Cosmetically acceptable response to therapy (>75% clearance) was achieved in 37 (84.1%) patients. Wart response at distant sites was seen in 38 (86.3%) patients. Thirty‑six patients (81.8%) experienced mild therapy‑related side effects. Eighteen patients with complete response were followed up for 5.27 ± 1.7 months and none had recurrence of lesions. Conclusions: Killed Mw vaccine is safe and effective in the treatment of extensive cutaneous warts. Larger, preferably randomized controlled trials are needed to assess its efficacy vis a vis standard therapies for warts.

Treatment of common warts with the immune stimulant Propionium bacterium parvum / Tratamento das verrugas vulgares com o imunoestimulante Propionium bacterium parvum

BACKGROUND: Warts are epithelial proliferations in the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in size and number according to the patient's immune status. The Propionium bacterium parvum is a strong immune stimulant and immune modulator and has important effects in the immune system and it is able to produce antibodies in the skin. OBJECTIVE: To show the efficacy of the Propionium bacterium parvum in saline solution in the treatment of skin warts. METHODS: A randomized double-blind study. Twenty patients with multiple warts were divided into two groups: one received 0,1ml intradermal injection of placebo solution in just one of the warts and the other received 0,1 ml of saline solution of Propionium bacterium parvum, one dose a month, for 3 to 5 months. RESULTS: Among the 20 patients who participated in the study, ten received the placebo and ten received the saline solution with Propionium bacterium parvum. In 9 patients treated with the Propionium bacterium parvum solution the warts disappeared without scars and in 1 patient it decreased in size. In 9 patients who received the placebo no change to the warts was observed and in 1 it decreased in size. CONCLUSIONS: The immune modulator and immune stimulant Propionium bacterium parvum produced antibodies in the skin which destroyed the warts without scars, with statistically significant results (P<0,001), and cured 90 % of the patients. We suggest the use of the immune stimulant in the treatment of warts.

FUNDAMENTOS: Verrugas são proliferações epiteliais na pele e mucosas causadas por diversos tipos de HPV. Elas podem involuir espontaneameme ou aumentar em número e tamanho de acordo com estado imunitário do paciente. O Propionium bacterium parvum é urn potente imunoestimulador e imunomodulador e tem efeitos importantes no sistema imune e é capaz de produzir anticorpos na pele. OBJETIVO: Mostrar a eficácia do Propionium bacterium parvum diluído em solução salina no tratamento de verrugas cutâneas. MÊTODOS: Estudo duplo-cego randomizado. Vinte pacientes com verrugas múltiplas foram divididos em dois grupos, um recebeu aplicação intradérmica do placebo em uma (1) única verruga e o outro da solução salina com Propionium bacterium parvum, uma dose por mês por 3 a 5 meses. RESULTADOS: Dos 20 pacientes do estudo, dez receberam placebo e 10 de solução salina com Propionium bacterium parvum. Dos pacientes tratados com Propionium bacterium parvum nove (9) foram curados e um teve diminuição das lesões. Do grupo do placebo nove (9) não apresentaram alterações e 1 (um) apresentou diminuição das lesões. CONCLUSÔES: O imunomodulador e imunoestimulador Propionium bacterium parvum produz anticorpos na pele que destroem as verrugas sem cicatrizes e mostrou uma significância de P<0,001, com cura de 90% dos pacientes submetidos à terapia. Sugerimos a utilização de imunoestimulante para o tratamento de verruga vulgar.

Efectividad de la pomada de urea en las verrugas plantares / Effectiveness of the urea ointment in the feet warts

Se hizo un ensayo clinicoterapéutico en 60 pacientes atendidos en la consulta de Dermatología del Hospital Provincial Docente Dr Joaquín Castillo Duany de Santiago de Cuba, durante el 2008, con el fin evaluar la efectividad de la pomada de urea en las verrugas plantares. Se conformaron 2 grupos (de estudio y control): los primeros recibieron pomada de urea al 20 por ciento y los segundos pomada salicílica al 40 por ciento. La pomada de urea resultó más eficaz para eliminar las manifestaciones clínicas de esa lesión, en un período de 6 a 8 semanas y no hubo reacciones adversas.

A clinical therapeutical trial was made in 60 patients assisted at the Dermatology department of Dr Joaquín Castillo Duany Teaching Provincial Hospital from Santiago de Cuba, during 2008, aimed at evaluating the effectiveness of the urea ointment in the feet warts. They conformed to 2 groups (study and control): the first group received urea ointment at 20 percent and the second one salicylic ointment at 40 percent. The urea ointment was more effective to eliminate the clinical manifestations of that lesion, in a period of 6 to 8 weeks and there were not adverse reactions.

Comparação entre a eficácia da cimetidina e do sulfato de zinco no tratamento de verrugas múltiplas e recalcitrantes / Efficacy comparison between cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts

FUNDAMENTOS: Verrugas são proliferações epiteliais na pele e mucosas causadas por diversos tipos de HPV. Elas podem involuir espontaneamente ou aumentar em número e tamanho de acordo com estado imunitário do paciente. A cimetidina e o sulfato de zinco têm importante efeito no sistema imune, sendo usados como imunomoduladores no tratamento de diversas doenças. OBJETIVO:Comparar a eficácia terapêutica de cimetidina e sulfato de zinco no tratamento de verrugas cutâneas de difícil tratamento. MÉTODOS: Estudo prospectivo duplo-cego randomizado. Dezoito pacientes com verrugas múltiplas foram divididos em dois grupos, um recebeu cimetidina 35mg/kg/dia (máximo 1.200mg/dia), e o outro, sulfato de zinco 10mg/kg/dia (máximo de 600mg/dia) por três meses. RESULTADOS: Dos 18 pacientes do estudo, nove receberam cimetidina, e nove, sulfato de zinco; apenas um do grupo do sulfato de zinco não completou o tratamento devido a náuseas e vômitos. Cura foi obtida em cinco pacientes tratados com sulfato de zinco, e apenas um não obteve alteração das lesões. Do grupo da cimetidina cinco não apresentaram modificação, e quatro apresentaram diminuição inferior a 30% das lesões iniciais. CONCLUSÕES: Sulfato de zinco na dose de 10mg/kg/dia parece ser mais efetivo que cimetidina para o tratamento de crianças e adultos com verrugas múltiplas e de difícil manejo. A pequena casuística deste trabalho não permite, entretanto, conclusão categórica.

Background: Warts are epithelial proliferations on the skin and mucous membrane caused by various types of HPV. They can decrease spontaneously or increase in number and size according to patient's immune status. Cimetidine and zinc sulphate have important effects on the immune system and are used as immunomodulators in the treatment of various diseases. Objective: To compare the efficacy of cimetidine and zinc sulphate in the treatment of multiple and recalcitrant warts. Methods: A random double-blind prospective study. Eighteen patients with multiple warts were divided into two groups: one took 35mg/Kg/day of cimetidine (maximum 1200 mg/day) and the other 10 mg/Kg/day of zinc sulphate (maximum 600 mg/day) for three months. Results: Among the 18 patients who participated in the study, nine took cimetidine and nine zinc sulphate. Just one patient in the zinc sulphate group did not complete treatment due to nausea and vomiting. Five patients who were treated with zinc sulphate were cured and only one did not show modifications in lesions. Among the group who was treated with cimetidine, five did not show modifications in lesions and four showed decrease from baseline below 30%. Conclusions: 10 mg/Kg/day zinc sulphate dose seems to be more effective than cimetidine for the treatment of children and adults with multiple and difficult-to-handle warts. However, the small number of patients did not enable any definitive conclusion.

Imiquimod en crema al 5% en el tratamiento de verrugas anogenitales asociadas a VPH: experiencia preliminar / Imiquimod 5% cream in the treatment of anogenital warts HPV associated

Antecedentes: La infección persistente por VPH de alto riesgo se asocia con cáncer cervicouterino, encontrándosepositividad en el 99,7% de los casos. Las verrugas anogenitales son una forma de presentación de la infección persistente. Objetivo: Investigar la eficacia y seguridad de imiquimod en crema al 5%, en el tratamiento de las verrugas anogenitales en mujeres. Método: Estudio prospectivo no randomizado, en mujeres portadoras de verrugas anogenitales asociadas a VPH. El tratamiento consiste en la autoaplicación de imiquiomod en crema al 5% tres veces a la semana por hasta un período de 16 semanas. Se define como respuesta completa al tratamiento aquella en que desaparece completamente la lesión; por respuesta parcial la disminución de al menos un 50% del volumen inicial de la lesión. Resultados: Durante un período de 8 meses fueron ingresadas y tratadas 38 pacientes La duración del tratamiento varió entre 1 y 4 meses. El número promedio de aplicaciones fue de 28,7. El 66% (25 casos) de las pacientes presentaron una respuesta completa, en tres casos no hubo respuesta, uno de ellos en una paciente inmunodeprimida, en 10 casos hubo respuestas parciales. En las pacientes con respuestas completas se necesitó un promedio de 28,7 aplicaciones hasta obtener el resultado. Conclusiones: Imiquimod es un fármaco con buena efectividad y seguridad en el tratamiento de las verrugas anogenitales asociadas a VPH, en tratamiento de tres veces por semana durante mínimo de 10 semanas.

Background: The chronic infection by high-risk HPV serotypes is strongly associated with cervical cancer, detection of HPV on tissue sample has been reported 99.7% of cases. The anal-genital warts represent the clinical manifestation of the persistent infection by this virus. Objectives: To investigate the efficacy and safety of Imiquimod cream 5% concentration, in the treatment of anal-genital warts in women. Methods: A non-randomized prospective study in women diagnosed with anal-genital warts HPV associated. The treatment consists in self-application of imiquimod cream 5%, three times a week for a period of 16 weeks or more. We define complete response to treatment in those patients where the lesion disappeared completely, and partial response to those where the lesion declined at least 50% of its initial volume. Results: Over a period of 8 months were admitted to the study and treated a total of 38 patients. Treatment duration varied between 1 and 4 months. The average number of applications was 28.7 times. 66% (25 cases) of the patients had a complete response, in three cases there was no response, one of them was an immunodepressed patients, in 10 cases there was partial response. The patients with complete response needed an average of 28.7 applications to get that result. Conclusions: Imiquimod is a drug with high effectiveness and safety in the treatment of anal-genital warts HPV associated, in a three times per week and at least 10 weeks total duration treatment.

Tratamiento de verruga plantar recalcitrante con terapia fotodinámica / Treatment of recalcitrant verruca plantaris with photodynamic therapy

Se presenta el caso de un paciente de sexo masculino, de 55 años de edad, portador de una verruga plantar recalcitrante de casi dos años de evolución. El paciente fue tratado con terapia fotodinámica utilizando metil aminolevulinato y una fuente de luz roja de 630 mm, con una dosis de 37 J/cm2. Luego de tres sesiones de terapia fotodinámica, el paciente presentó una remisión completa de la verruga plantar, lo que ha persistido luego de ocho meses de seguimiento y con excelente resultado cosmético.

We present the case of a 55-year-old male patient with recalcitrant verruca plantaris for almost two years. The patient was treated with photodynamic therapy using aminolevulinic acid and a red light source (630 nm), with a 37 J/cm2 dose. After three photodynamic therapy sessions, the patient showed a complete remission and is still free of the lesion after 8 months of follow-up, evidencing an excellent cosmetic outcome.

Tratamiento de las verrugas vulgares en niños con la hemolinfa del insecto Epicauta sp / Treatment of the viral warts in children with the hemolymph of the insect epicauta sp

La verruga vulgar es una enfermedad viral frecuente en los niños de Huancayo, se observó que desde hace tiempo en forma empírica los habitantes curaban las verrugas con la hemolinfa del insecto Epicauta sp. Se realizó el estudio en niños con verruga en las manos entre 5 y 12 años de edad; 36 fueron varones y 24 mujeres. Los niños en forma aleatoria fueron asignados en dos grupos de tratamiento, uno con nitrógeno líquido (n=30) y el otro con hemolinfa del Epicauta sp (n=30). Se realizó tres aplicaciones, una cada semana y se evaluó los resultados al mes de iniciado el tratamiento. En el grupo tratado con nitrógeno líquido ocho niños abandonaron el tratamiento por dolor. En el grupo tratado con hemolinfa Epicauta. 18 presentaron formación de ampollas, cuatro eritema y sólo dos abandonaron el tratamiento por presentar dermatitis de contacto, Nuestro objetivo fue comparar la efectividad del uso de hemolinfa del insecto Epicauta sp. con el uso de nitrógeno líquido en el tratamiento de las verrugas vulgares en niños. Del total de pacientes que se trató con nitrógeno líquido, 18 pacientes (82 por ciento) fueron curados y cuatro no respondieron; de los tratados con hemolinfa de epicauta sp. 23 pacientes (82 por ciento) fueron curados y cinco no respondieron.

Bleomicina: Una opción en el tratamiento de las verrugas / Bleomicyn: An alternative in the treatment of verrucae

El sulfato de bleomicina ha sido utilizado en forma eficaz en el tratamiento de verrugas vulgares recalcitrantes. Se realizó un estudio en 55 pacientes con verrugas de diversas localizaciones. El 90.9 por ciento obtuvo curación completa en la primera sesión; el 9.01 por ciento experimentó mejoría, ameritando dos sesiones posteriores, sin presentar recidivas a un año de observación

Cimetidina en el tratamiento de verrugas vulgares [carta] / Cimetidine in the treatment of viral warts

Se reportan los casos de dos niños con verrugas vulgares diseminadas que respondieron favorablemente al tratamiento con cimetidina por vía bucal. La actividad inmunomoduladora de la cimetidina se ha sugerido como posible mecanismo de acción

DNCB: tratamento de verrugas em crianças / DNCB: tratment of warts in children

Os autores analisaram 31 pacientes (grupo-teste) portadores de verrugas submetidos a imunoestimulaçäo com dinitroclorobenzeno (DNCB) a 2%, procurando analisar a eficácia desse tratamento na regressäo das lesöes. A idade dos pacientes variou de dois a 16 anos, 20 do sexo masculino e 18 do sexo feminino. Observaron também 13 pacientes (grupo controle) portadores de verrugas submetidos a tratamento com placebo, com idade variando de dois a 17 anos, sete do sexo masculino e seis do sexo feminino. Os resultados demonstraram que houve regressäo total das verrugas em 20 pacientes (62,5%) e regressäo parcial em três (9,4%). Somente nove (28,1%) näo apresentaram regressäo das mesmas. Embora 18 pacientes (56,2%) relatassem a ocorrência de efeitos colaterais como eritema, edema e dor no local da aplicaçäo do DNCB a 2%, concluiu-se que a resposta terapêutica ao DNCB foi satisfatória

Tratamiento de verrugas vulgares múltiples y recalcitrantes con 1-cloro-2, 4 dinitrobenceno (DNCB) o placebo en pacientes pediátricos / Treatment of warts multiples and recalcitrants with 1-chlore-2, 4 dinitrobencene (DNCB) and placebo in pediatric patients

Se estudiaron en forma abierta y controlada 40 pacientes pediátricos con verrugas vulgares múltiples, resistentes a otros tratamientos. En 20 pacientes se empleó como agente terapéutico el 1-cloro-2, 4 dinitrobenceno (DNCB) y en 20 pacientes acetona como placebo. Curaron 16 pacientes tratados con DNCB y siete tratados con placebo (P < 0.025). El tiempo promedio de curación de las lesiones con DNCB fue de siete semanas. La edad, sexo, número de lesiones, localización, tratamientos previos y tiempo de evolución de las lesiones no influyeron en la respuesta terapéutica

Intoxicaçäo sistêmica por podofilina: relato de um caso fatal / Sistemic intoxication by podophyllum: report of a fatal case

Relata-se um caso fatal de intoxicaçäo sistêmica por podofilina, que apreentou quadro neurológico grave, com tetraplegia e arreflexia global intermitente, elevaçäo de aminotransferases, enzimas musculares e acentuada leucocitose. Duas biópsias consecutivas revelaram miosite externa e a eletromiografia polineuropatia grave